1
|
Casais R, Iglesias N, Sevilla IA, Garrido JM, Balseiro A, Dominguez M, Juste RA. Non-specific effects of inactivated Mycobacterium bovis oral and parenteral treatment in a rabbit scabies model. Vet Res 2024; 55:41. [PMID: 38532491 DOI: 10.1186/s13567-024-01293-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Accepted: 02/24/2024] [Indexed: 03/28/2024] Open
Abstract
Tuberculosis BCG vaccination induced non-specific protective effects in humans led to postulate the concept of trained immunity (TRAIM) as an innate type of immune mechanism that triggered by a pathogen, protects against others. Killed vaccines have been considered not to be effective. However, field efficacy of a commercial vaccine against paratuberculosis, as well as of a recently developed M. bovis heat-inactivated vaccine (HIMB) prompted to test whether it could also induce TRAIM. To this, we used a sarcoptic mange rabbit model. Twenty-four weaned rabbits were treated orally or subcutaneously with a suspension of either HIMB (107 UFC) or placebo. Eighty-four days later the animals were challenged with approximately 5000 S. scabiei mites on the left hind limb. Skin lesion extension was measured every 2 weeks until 92 days post-infection (dpi). Two animals were killed at 77 dpi because of extensive skin damage. The rest were euthanized and necropsied and the lesion area and the mite burden per squared cm were estimated. Specific humoral immune responses to S. scabiei and to M. bovis were investigated with the corresponding specific ELISA tests. Subcutaneously and orally HIMB vaccinated animals compared with placebo showed reduced lesion scores (up to 74% and 62%, respectively) and mite counts (-170% and 39%, respectively). This, together with a significant positive correlation (r = 0.6276, p = 0.0031) between tuberculosis-specific antibodies and mite count at 92 dpi supported the hypothesis of non-specific effects of killed mycobacterial vaccination. Further research is needed to better understand this mechanism to maximize cross protection.
Collapse
Affiliation(s)
- Rosa Casais
- Area de Sanidad Animal, SERIDA, 33394, Gijon, Asturias, Spain
- NySA Group, SERIDA, 33300, Villaviciosa, Asturias, Spain
| | - Natalia Iglesias
- Area de Sanidad Animal, SERIDA, 33394, Gijon, Asturias, Spain
- NySA Group, SERIDA, 33300, Villaviciosa, Asturias, Spain
| | - Iker A Sevilla
- Departamento de Sanidad Animal, NEIKER-BRTA, 48160, Derio, Bizkaia, Spain
| | - Joseba M Garrido
- Departamento de Sanidad Animal, NEIKER-BRTA, 48160, Derio, Bizkaia, Spain
| | - Ana Balseiro
- Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad de León, 24071, León, León, Spain
- NySA Group, SERIDA, 33300, Villaviciosa, Asturias, Spain
| | - Mercedes Dominguez
- Unidad de Inmunología Microbiana, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220, Majadahonda, Madrid, Spain
| | - Ramon A Juste
- Departamento de Sanidad Animal, NEIKER-BRTA, 48160, Derio, Bizkaia, Spain.
- NySA Group, SERIDA, 33300, Villaviciosa, Asturias, Spain.
| |
Collapse
|
2
|
Abstract
The control and prevention of bovine viral diarrhea virus (BVDV) infections has provided substantial challenges. Viral genetic variation, persistent infections, and viral tropism for immune cells have complicated disease control strategies. Vaccination has, however, provided an effective tool to prevent acute systemic infections and increase reproductive efficiency through fetal protection. There has been substantial controversy about the safety and efficacy of BVDV vaccines, especially when comparing killed versus modified-live viral (MLV) vaccines. Furthermore, numerous vaccination protocols have been proposed to protect the fetus and ensure maternal antibody transfer to the calf. These issues have been further complicated by reports of immune suppression during natural infections and following vaccination. While killed BVDV vaccines provide the greatest safety, their limited immunogenicity makes multiple vaccinations necessary. In contrast, MLV BVDV vaccines induce a broader range of immune responses with a longer duration of immunity, but require strategic vaccination to minimize potential risks. Vaccination strategies for breeding females and young calves, in the face of maternal antibody, are discussed. With intranasal vaccination of young calves it is possible to avoid maternal antibody interference and induce immune memory that persists for 6-8 months. Thus, with an integrated vaccination protocol for both breeding cows and calves it is possible to maximize disease protection while minimizing vaccine risks.
Collapse
|
3
|
Chamchod F, Cosner C, Cantrell RS, Beier JC, Ruan S. Transmission Dynamics of Rift Valley Fever Virus: Effects of Live and Killed Vaccines on Epizootic Outbreaks and Enzootic Maintenance. Front Microbiol 2016; 6:1568. [PMID: 26869999 PMCID: PMC4740790 DOI: 10.3389/fmicb.2015.01568] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2015] [Accepted: 12/27/2015] [Indexed: 01/14/2023] Open
Abstract
Rift Valley fever virus (RVFV) is an arthropod-borne viral pathogen that causes significant morbidity and mortality in small ruminants throughout Africa and the Middle East. Due to the sporadic and explosive nature of RVF outbreaks, vaccination has proved challenging to reduce RVFV infection in the ruminant population. Currently, there are two available types of vaccines, live and killed, in endemic areas. In this study, two mathematical models have been developed to explore the impact of live and killed vaccines on the transmission dynamics of RVFV. We demonstrate in general that vaccination helps reduce the severity of RVF outbreaks and that less delay in implementation and more vaccination attempts and effective vaccines can reduce the outbreak magnitude and the endemic number of RVFV. However, an introduction of a number of ruminants vaccinated by live vaccines in RVFV-free areas may cause an outbreak and RVFV may become endemic if there is sustained use of live vaccines. Other factors that are the important determinants of RVF outbreaks include: unsustained vaccination programs, recruitment of susceptible ruminants, and the seasonal abundance of mosquitoes.
Collapse
Affiliation(s)
- Farida Chamchod
- Department of Mathematics, Faculty of Science, Mahidol University Bangkok, Thailand
| | - Chris Cosner
- Department of Mathematics, University of Miami Coral Gables, FL, USA
| | | | - John C Beier
- Department of Public Health Sciences, Miller School of Medicine, University of Miami Miami, FL, USA
| | - Shigui Ruan
- Department of Mathematics, University of Miami Coral Gables, FL, USA
| |
Collapse
|
4
|
Bolhassani A, Muller M, Roohvand F, Motevalli F, Agi E, Shokri M, Rad MM, Hosseinzadeh S. Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania. Hum Vaccin Immunother 2015; 10:3499-508. [PMID: 25668661 DOI: 10.4161/21645515.2014.979606] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
The development of an efficient vaccine against high-risk HPV types can reduce the incidence rates of cervical cancer by generating anti-tumor protective responses. Traditionally, the majority of prophylactic viral vaccines are composed of live, attenuated or inactivated viruses. Among them, the design of an effective and low-cost vaccine is critical. Inactivated vaccines especially heat-killed yeast cells have emerged as a promising approach for generating antigen-specific immunotherapy. Recent studies have indicated that yeast cell wall components possess adjuvant activities. Moreover, a non-pathogenic protozoan, Leishmania tarentolae (L.tar) has attracted a great attention as a live candidate vaccine. In current study, immunological and protective efficacy of whole recombinant killed Pichia pastoris and Leishmania tarentolae expressing HPV16 L1 capsid protein was evaluated in tumor mice model. We found that Pichia-L1, L.tar-L1 and Gardasil groups increase the IgG2a/IgG1 ratio, indicating a relative preference for the induction of Th1 immune responses. Furthermore, subcutaneous injection of killed Pichia-L1 generated the significant L1-specific IFN-γ immune response as well as the best protective effects in vaccinated mice as compared to killed L.tar-L1, killed Pichia pastoris, killed L.tar and PBS groups. Indeed, whole recombinant Leishmania tarentolae could not protect mice against C3 tumor mice model. These data suggest that Pichia-L1 may be a candidate for the control of HPV infections.
Collapse
Key Words
- 2-ME, mercaptoethanol
- AOX1, alcohol oxidase I gene
- ConA, concanavalin A
- DAB, 3,3′-diaminobenzidine
- FACS, fluorescence-activated cell sorting
- GFP, green fluorescent protein
- HPV, human papillomaviruses
- KBMA, killed but metabolicallyactive
- L.tar, Leishmania tarentolae
- L1 capsid protein
- Leishmania tarentolae expression system
- Pichia pastoris expression system
- SD, standard deviation
- Yeast-HBsAg, yeast expressing hepatitis B surface antigen
- cervical cancer
- human papillomavirus
- killed vaccine
- rL1, recombinant L1
Collapse
Affiliation(s)
- Azam Bolhassani
- a Department of Hepatitis and AIDs; Pasteur Institute of Iran ; Tehran , Iran.
| | | | | | | | | | | | | | | |
Collapse
|